RHHBY Stock Recent News

Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S. manufacturing.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil). The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus by 32%. For the key secondary end.

Basel, 25 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).1 The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus by 32%.1 For the key secondary endpoint of influenza virus transmission resulting in symptoms, Xofluza showed a clinically meaningful reduction although statistical significance was not reached. Xofluza was well tolerated, with no new safety signals identified.1

Roche Holding AG (OTCQX:RHHBY) Q1 2025 Sales/ Trading Statement Call April 24, 2025 8:00 AM ET Company Participants Thomas Schinecker - Chief Executive Officer Alan Hippe - Chief Financial & Information Officer Teresa Graham - Chief Executive Officer, Roche Pharmaceuticals Matt Sause - Chief Executive Officer, Roche Diagnostics Bruno Eschli - Head, Investor Relations Conference Call Participants Sachin Jain - Bank of America Matthew Weston - UBS Emily Field - Barclays Justin Smith - Bernstein James Quigley - Goldman Sachs Kerry Holford - Berenberg Sarita Kapila - Morgan Stanley Simon Baker - Redburn Richard Vosser - JPMorgan Peter Verdult - BNP Paribas David Evans - Kepler Operator Ladies and gentlemen, welcome to Roche First Quarter Sales Webinar 2025. My name is Henrik, and I'm the technical operator for today's call.

RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.

Roche is seeking relief from US import tariffs, arguing that its exports of American-made drugs and diagnostics offset the value of products it ships into the country. Reporting a conference call with chief executive Thomas Schinecke, Reuters said the Swiss pharma giant is engaged in ongoing discussions with officials in President Donald Trump's administration, highlighting concerns that a strict push for domestic-only production could sharply increase costs.

Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the products it ships into the United States are offset by its exports of U.S.-made drugs and diagnostics.

Roche posted higher sales that beat analysts' expectations on higher demand for its key drugs.

Swiss drugmaker Roche said on Thursday its first-quarter sales rose 7% to 15.44 billion Swiss francs ($18.64 billion) and it confirmed its full-year guidance.

Basel, 23 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of its innovative Chest Pain Triage algorithm as part of the navifyⓇ Algorithm Suite. This groundbreaking algorithm is designed to more quickly and accurately detect Acute Coronary Syndrome (ACS) in patients presenting with chest pain, one of the most common reasons for Emergency Department (ED) visits. As EDs are typically one of the most crowded hospital units, leading to challenges to swiftly diagnose critical conditions, such as chest pain.4 This new algorithm was developed in collaboration with Universitätsklinikum Heidelberg.